RE: Investor meet presentation4 May 2024 11:41
You're using IMC so go to the interims presentation from less than seven months ago...
Look at slide 18, estimated annual prescriptions for 2024 - 'greater than 350,000'. Now apparently that was only a broker target and not their own and they've disassociated themselves from it but it was in their own slides not long ago!!
Page 22, 'achieve cash flow positive by YE 2024, revenues expected to exceed $120m by 2025' - that $120m requires around 500,000 prescriptions at ~$220 net Rx + milestone payments/royalties. In other words by next Q1 they'd need prescriptions to rise from 28000 to over 100,000 and still growing QoQ!
You can believe their word all you like but the last target for reaching cash flow positive was pushed back months after it was made - is it that likely to suddenly be achieved now when the numbers are so, so far off what they were estimating not long ago?
As for confirming they don't need an equity raise how about the presentation in April 2023 where in one slide it clearly states 'Fully funded to support operations through to cash flow break-even by YE 2024' as well as well as the same answer in response to the question in the Q&A of 'is the cash sufficient to get us to cash flow break even?' ... five months later an equity raise.